Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
55.94
+1.14 (2.08%)
At close: Jan 21, 2025, 4:00 PM
59.06
+3.12 (5.58%)
After-hours: Jan 21, 2025, 6:44 PM EST
Halozyme Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for HALO stock have an average target of 60.89, with a low estimate of 49 and a high estimate of 73. The average target predicts an increase of 8.85% from the current stock price of 55.94.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HALO stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 4 | 3 | 2 | 2 | 2 | 2 |
| Hold | 2 | 3 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $62 → $57 | Hold | Maintains | $62 → $57 | +1.89% | Jan 13, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $52 → $53 | Hold | Maintains | $52 → $53 | -5.26% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $68 → $70 | Strong Buy | Maintains | $68 → $70 | +25.13% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $68 | Strong Buy | Reiterates | $68 | +21.56% | Dec 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $68 | Strong Buy | Reiterates | $68 | +21.56% | Dec 18, 2024 |
Financial Forecast
Revenue This Year
1.02B
from 829.25M
Increased by 23.12%
Revenue Next Year
1.18B
from 1.02B
Increased by 15.48%
EPS This Year
4.23
from 2.10
Increased by 101.38%
EPS Next Year
4.98
from 4.23
Increased by 17.70%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.3B | 1.6B | |||
| Avg | 1.0B | 1.2B | 1.4B | |||
| Low | 964.1M | 1.1B | 1.3B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 28.5% | 27.9% | 34.8% | |||
| Avg | 23.1% | 15.5% | 21.6% | |||
| Low | 16.3% | 8.0% | 12.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 4.41 | 5.67 | 7.83 | |||
| Avg | 4.23 | 4.98 | 6.45 | |||
| Low | 4.00 | 4.51 | 5.67 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 110.0% | 34.1% | 57.4% | |||
| Avg | 101.4% | 17.7% | 29.6% | |||
| Low | 90.4% | 6.6% | 14.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.